Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BONESUPPORT HOLDING AB ( (SE:BONEX) ) has provided an announcement.
BONESUPPORT reported preliminary net sales of 313 MSEK for the fourth quarter of 2025, corresponding to 36% growth at constant exchange rates, and full-year 2025 growth of 39.7%, broadly in line with its target of above 40% growth. Looking ahead, the company expects sales growth of more than 35% at constant exchange rates for full-year 2026, signaling continued strong momentum in its orthobiologics business and reinforcing its position as a high-growth medtech player ahead of the audited year-end report due in February.
The most recent analyst rating on (SE:BONEX) stock is a Hold with a SEK226.00 price target. To see the full list of analyst forecasts on BONESUPPORT HOLDING AB stock, see the SE:BONEX Stock Forecast page.
More about BONESUPPORT HOLDING AB
BONESUPPORT Holding AB is a Swedish medical technology company specializing in orthobiologics for the treatment of bone injuries. Listed on Nasdaq Stockholm, it develops and commercializes innovative injectable bio-ceramic bone graft substitutes, marketed under the CERAMENT brand, which remodel into the patient’s own bone and can elute drugs. The company is based in Lund, Sweden, conducts multiple clinical studies to demonstrate the clinical and health-economic benefits of its products, and reported net sales of SEK 899 million in 2024.
Average Trading Volume: 268,862
Technical Sentiment Signal: Hold
Current Market Cap: SEK12.17B
See more insights into BONEX stock on TipRanks’ Stock Analysis page.